Celularity R&D Spending Growth & History (CELU)
Celularity's r&d spending was $15.0M for fiscal 2025.
View full Celularity company overviewCelularity annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.0M | −$2.4M | −13.58% |
| 2024 | 2024-12-31 | $17.4M | −$13.1M | −42.93% |
| 2023 | 2023-12-31 | $30.5M | −$47.9M | −61.12% |
| 2022 | 2022-12-31 | $78.4M | −$10.0M | −11.31% |
| 2021 | 2021-12-31 | $88.4M | $35.6M | +67.63% |
| 2020 | 2020-12-31 | $52.7M | — | — |
Celularity quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $3.3M | −$481,000 | −12.57% |
| Q3 2025 | 2025-09-30 | $4.6M | $683,000 | +17.45% |
| Q2 2025 | 2025-06-30 | $3.4M | −$448,000 | −11.79% |
| Q1 2025 | 2025-03-31 | $3.7M | −$2.1M | −36.20% |
| Q4 2024 | 2024-12-31 | $3.8M | — | — |
| Q3 2024 | 2024-09-30 | $3.9M | −$1.3M | −24.45% |
| Q2 2024 | 2024-06-30 | $3.8M | −$4.8M | −55.83% |
| Q1 2024 | 2024-03-31 | $5.8M | −$11.1M | −65.53% |
| Q3 2023 | 2023-09-30 | $5.2M | −$15.2M | −74.54% |
| Q2 2023 | 2023-06-30 | $8.6M | −$16.7M | −66.06% |
| Q1 2023 | 2023-03-31 | $17.0M | −$4.7M | −21.79% |
| Q4 2022 | 2022-12-31 | $11.0M | −$13.7M | −55.48% |
| Q3 2022 | 2022-09-30 | $20.4M | −$3.4M | −14.37% |
| Q2 2022 | 2022-06-30 | $25.3M | $2.4M | +10.64% |
| Q1 2022 | 2022-03-31 | $21.7M | $4.7M | +27.56% |
| Q4 2021 | 2021-12-31 | $24.7M | — | — |
| Q3 2021 | 2021-09-30 | $23.8M | $12.5M | +111.87% |
| Q2 2021 | 2021-06-30 | $22.9M | — | — |
| Q1 2021 | 2021-03-31 | $17.0M | — | — |
| Q3 2020 | 2020-09-30 | $11.2M | — | — |
Celularity r&d spending trends
Over the last five fiscal years, Celularity's r&d spending decreased from $52.7M to $15.0M, a change of −$37.7M. The latest reported quarter, Q4 2025, shows $3.3M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Celularity source filings ↗